Biopharmaceutical

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

Retrieved on: 
Monday, July 31, 2023

“The Company’s progress is clear, and the impact of the changes we have made will continue to move us forward.

Key Points: 
  • “The Company’s progress is clear, and the impact of the changes we have made will continue to move us forward.
  • (Fix) Selling, general and administrative expenses were down 36% in the first quarter of 2023, compared to the same period in 2022.
  • (Fund/Propel) The Company launched its Strategic Partnership Initiative focused on developing long-term licensing revenue opportunities in Q3 2023.
  • “Our journey and our focus is to advance innovative technology to market, and to deliver value to our stockholders."

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

Retrieved on: 
Saturday, July 29, 2023

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB —from the Exchange.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB —from the Exchange.
  • The Company's Board of Directors has determined to appeal the Exchange's determination to commence delisting proceedings.
  • The Company's Board of Directors has determined to appeal the Exchange's determination to commence delisting proceedings.
  • Navidea intends to make arrangements to have its common stock quoted in the over-the-counter market if its common stock is delisted from the Exchange.

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Retrieved on: 
Thursday, July 27, 2023

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the hiring of Craig A. Dais, CPA in the position of Chief Financial Officer (CFO), reporting directly to the Company’s Chief Medical Officer.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the hiring of Craig A. Dais, CPA in the position of Chief Financial Officer (CFO), reporting directly to the Company’s Chief Medical Officer.
  • “Craig is an active and experienced accounting and finance leader with the ability to see both the details and the big picture,” said Michael Blue, M.D., FACEP, Navidea’s Chief Medical Officer.
  • His recent experience includes serving as Chief Financial Officer at Colorado Pain Care, LLC, (Fractional) Chief Financial Officer at Ascent CFO Solutions, Chief Financial Officer at Duffy Crane & Hauling, Vice President of Finance at Pendum LLC and other leadership positions with public and private organizations.
  • “I am thrilled to have the opportunity to join Navidea’s team as Chief Financial Officer, and eager to get started,” said Mr. Dais.

ImmunoTek Bio Centers Celebrates 10th Anniversary

Retrieved on: 
Wednesday, July 26, 2023

This month we celebrate the 10th anniversary of ImmunoTek Bio Centers, the world's largest and fastest-growing independent blood plasma collection company.

Key Points: 
  • This month we celebrate the 10th anniversary of ImmunoTek Bio Centers, the world's largest and fastest-growing independent blood plasma collection company.
  • ImmunoTek launched ten years ago to build and operate plasma donation centers nationwide to help meet the growing demand for blood plasma.
  • Since its formation on July 18, 2013, the company has accepted more than seven million paid donations at its collection centers.
  • We have an incredibly talented team and a solid operating platform that is fueling our growth for the next decade.”
    Through its two subsidiaries, ImmunoTek Plasma and Freedom Plasma, ImmunoTek Bio Centers operates 45 centers in 21 states, with over a dozen more in development.

CordenPharma Establishes World-Class Technology & Science Advisory Board of Experts Across Six Technology Platforms

Retrieved on: 
Wednesday, July 26, 2023

CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.

Key Points: 
  • CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.
  • The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.
  • Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms .
  • Dr. Michael Quirmbach, CEO & President at CordenPharma, said: "CordenPharma is honored to have the opportunity to work with these distinguished scientific experts.

CordenPharma Establishes World-Class Technology & Science Advisory Board of Experts Across Six Technology Platforms

Retrieved on: 
Wednesday, July 26, 2023

The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.

Key Points: 
  • The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.
  • CordenPharma's TSAB brings together eight scientific experts from various disciplines, including chemistry, pharmacology, biotechnology, and regulatory affairs.
  • Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms .
  • Dr. Michael Quirmbach, CEO & President at CordenPharma, said: "CordenPharma is honored to have the opportunity to work with these distinguished scientific experts.

Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

Retrieved on: 
Thursday, July 13, 2023

Separately, Amit Bhalla has stepped down from the Company’s Board.

Key Points: 
  • Separately, Amit Bhalla has stepped down from the Company’s Board.
  • Dana J Moss, JD joins Navidea’s Board of Directors with demonstrated leadership and legal expertise within innovative organizations focused on life sciences and technology driven products.
  • Separately, Amit Bhalla has decided to step down from the Board to focus on other business interests.
  • “We thank Amit Bhalla for his many contributions during his time with the Board,” said John K. Scott, Jr, Navidea’s Vice Chair of the Board.

Flash Therapeutics Appoints Jérôme Bédier as President to Accelerate its Biopharmaceutical CDMO Business Development

Retrieved on: 
Thursday, July 6, 2023

Jérôme Bédier, 49 years old, is an expert in the biomanufacturing and CDMO sector, to which he has devoted a large part of his career.

Key Points: 
  • Jérôme Bédier, 49 years old, is an expert in the biomanufacturing and CDMO sector, to which he has devoted a large part of his career.
  • With 25 years of experience, most particularly with the Novasep group, Jérôme Bédier held positions in business development and operations management before taking over strategic management of Novasep's Biopharmaceutical business and its three European sites.
  • "We are delighted to welcome Jérôme Bédier, an expert in biomanufacturing and service to the biopharmaceutical industry, to the executive management of Flash Therapeutics.
  • Jérôme Bédier added: "I am very pleased to join Flash Therapeutics in Toulouse.

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

Retrieved on: 
Monday, July 3, 2023

The safety profile of datopotamab deruxtecan was consistent with previous clinical trials with no new safety signals identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with previous clinical trials with no new safety signals identified.
  • Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
  • Patients without actionable genomic alterations were previously treated, concurrently or sequentially, with platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
  • AstraZeneca is also researching a potential diagnostic test to help identify patients most likely to benefit from treatment with datopotamab deruxtecan.

Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

Retrieved on: 
Friday, June 30, 2023

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the Company’s Board of Directors, in consultation with G2G Ventures as Executive Consultants, has unanimously rejected an unsolicited, non-binding offer from ProPhase Labs to acquire certain assets from the Company on the terms disclosed in their press release on June 29, 2023.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the Company’s Board of Directors, in consultation with G2G Ventures as Executive Consultants, has unanimously rejected an unsolicited, non-binding offer from ProPhase Labs to acquire certain assets from the Company on the terms disclosed in their press release on June 29, 2023.
  • “After careful review and consideration of ProPhase Labs’ unsolicited proposal, our Board determined that the proposal substantially undervalues Navidea’s assets, is opportunistic, and is not in the best interest of our stockholders,” said Josh Wilson, Navidea’s Director.
  • “While we certainly understand and are appreciative of the interest in Navidea’s unique technologies, the Board is confident that the Company’s stated objectives and its Fix, Fund, Propel approach to advancing our innovations to market will generate far superior long-term value for stockholders.”
    The Company, with G2G Ventures as Executive Consultants, recently announced the receipt of $7.5 million cash from Cardinal Health in lieu of a contingent milestone payment, and provided additional insight on its recent performance in line with its Fix, Fund, Propel approach.